Nymox provides update on Phase 2 prostate cancer clinical trial

theflyonthewall.com

Nymox provided an update on U.S. Phase 2 prostate cancer clinical trial activities for NX-1207, the company's new investigational drug being tested for early stage prostate cancer. The prostate cancer trial has reached the halfway point in patient recruitment. Safety assessments to date have been positive with no serious or unexpected adverse effects related to the drug.

Rates

View Comments (0)